1,370 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Crowley Wealth Management Inc.

Crowley Wealth Management Inc. bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,370 shares of the medical instruments supplier’s stock, valued at approximately $311,000.

A number of other institutional investors also recently added to or reduced their stakes in BDX. Principal Financial Group Inc. lifted its position in Becton, Dickinson and Company by 1.5% in the third quarter. Principal Financial Group Inc. now owns 1,179,715 shares of the medical instruments supplier’s stock valued at $284,429,000 after acquiring an additional 16,918 shares during the last quarter. Citizens Financial Group Inc. RI lifted its position in Becton, Dickinson and Company by 4.1% in the third quarter. Citizens Financial Group Inc. RI now owns 3,942 shares of the medical instruments supplier’s stock valued at $950,000 after purchasing an additional 157 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $461,000. Raymond James Trust N.A. boosted its stake in shares of Becton, Dickinson and Company by 1.8% in the third quarter. Raymond James Trust N.A. now owns 12,891 shares of the medical instruments supplier’s stock valued at $3,108,000 after buying an additional 231 shares in the last quarter. Finally, CFS Investment Advisory Services LLC purchased a new position in Becton, Dickinson and Company in the third quarter worth $1,131,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BDX. Barclays boosted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, March 5th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and an average target price of $278.29.

Insider Activity

In other news, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Down 0.5 %

NYSE BDX opened at $230.63 on Friday. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99. The company’s fifty day simple moving average is $232.58 and its 200-day simple moving average is $231.97. The stock has a market cap of $66.22 billion, a P/E ratio of 38.31, a PEG ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.80%. Becton, Dickinson and Company’s payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.